Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Manifestations, Prevalence, Management and Outcome of Invasive Aspergillosis in Post-Liver Transplant Patients

Author(s): Mohsen Aliakbarian, Rozita Khodashahi*, Kambiz Akhavan Rezayat, Hamid Reza Naderi, Mandana Khodashahi, Maziar Mortazavi Pasand, Ebrahim Khaleghi and Maliheh Dadgar Moghaddam

Volume 19, Issue 1, 2024

Published on: 11 January, 2023

Page: [61 - 69] Pages: 9

DOI: 10.2174/1574886318666221206102653

Price: $65

Abstract

Background: Aspergillosis is a severe and fatal complication that causes infection in transplant recipients and patients with immunodeficiency syndrome, neutropenia, chronic granulomatosis, and hematologic malignancies. Invasive Aspergillosis has been reported as one of the fungal infections with high mortality in transplant recipients. This study aimed to describe the manifestations, prevalence, management and outcome of invasive Aspergillosis fungal infections in liver transplant patients.

Methods: This descriptive cross-sectional study was conducted on patients with liver transplantation who were infected with invasive Aspergillosis fungal infections. The data were extracted from the medical records of the archive of Montasryieh Hospital, Mashhad, Iran, between August 2019 and August 2020.

Results: In general, 86 patients who had liver transplantation were hospitalized at Montasryieh Hospital from August 2019 to August 2020. Among them, 10 patients were infected with invasive Aspergillosis. Only 6.7% of the patients were categorized under late-onset (> 90 days after liver transplantation), and 93.3% of them were early-onset (< 90 days after liver transplantation). Invasive Aspergillosis fungal infections were suspected based on clinical or radiological signs (possible in 30% of cases; n = 3). The probable diagnosis was reported in 60% (n = 6), and the proven diagnosis was observed only in one patient. In addition, 80% of the patients were diagnosed with Pulmonary Aspergillosis, and two patients had pulmonary Aspergillosis in combination with the central nervous system and cutaneous Aspergillosis. A correlation was found between a comorbid disease and the type of Aspergillosis (r = 0.69; P = 0.02). Voriconazole was effective to treat invasive Aspergillosis in all patients.

Conclusion: The prevalence rate of Aspergillosis is relatively high among liver transplant recipient populations (11%). All recipients infected with Aspergillosis had at least one risk factor, including an underlying disease. It seems that Voriconazole therapy is effective among transplant patients with pulmonary Aspergillosis.

« Previous Next »
Graphical Abstract

[1]
Aït-Ammar N, Levesque E, Murat JB, et al. Aspergillus pseudodeflectus: A new human pathogen in liver transplant patients. BMC Infect Dis 2018; 18(1): 648.
[http://dx.doi.org/10.1186/s12879-018-3527-5] [PMID: 30541477]
[2]
Utsumi M, Umeda Y, Yagi T, et al. Risk analysis for invasive fungal infection after living donor liver transplantation: Which patient needs potent prophylaxis? Dig Surg 2019; 36(1): 59-66.
[http://dx.doi.org/10.1159/000486548] [PMID: 29649828]
[3]
Shoham S. Emerging fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 2013; 27(2): 305-16.
[http://dx.doi.org/10.1016/j.idc.2013.02.004] [PMID: 23714342]
[4]
Hedayati MT, Khodavaisy S, Aliali M. A review on invasive Aspergillosis in patients admitted to intensive care unit with emphasis on diagnostic methods. J Mazandaran Univ Med Sci 2010; 19(74): 99-112.
[5]
Neyra KM, Brizendine KD. Retrospective study evaluating the performance of risk factors for invasive mold infections in liver transplantation. Transpl Infect Dis 2020; 22(1): e13223.
[http://dx.doi.org/10.1111/tid.13223] [PMID: 31782873]
[6]
Zahmatkeshan M, Amirian A. Investigation of post-transplant early infections and their risk factors. Sadra Med J 2015; 3(2): 107-18.
[7]
Wróblewska M, Sulik-Tyszka B, Figiel W, Niewiński G, Zieniewicz K. Invasive Aspergillosis in transplant recipients. In: Surgical Recovery; IntechOpen: London, 2019; pp. 81.
[8]
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 2008; 46(12): 1813-21.
[http://dx.doi.org/10.1086/588660] [PMID: 18462102]
[9]
Hassan EA, El-Rehim ASA, Hassany SM, Ahmed AO, Elsherbiny NM, Mohammed MH. Fungal infection in patients with end-stage liver disease: Low frequency or low index of suspicion. Int J Infect Dis 2014; 23: 69-74.
[http://dx.doi.org/10.1016/j.ijid.2013.12.014] [PMID: 24726663]
[10]
Guan X-D, He X-S, Chen J, et al. Fungal infection in patients after liver transplantation in years 2003 to 2012. Ann Transplant 2012; 17(4): 59-63.
[http://dx.doi.org/10.12659/AOT.883695] [PMID: 23274325]
[11]
Balogh J, Gordon Burroughs S, Boktour M, et al. Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients. Liver Transpl 2016; 22(2): 163-70.
[http://dx.doi.org/10.1002/lt.24365] [PMID: 26515643]
[12]
Nagao M, Fujimoto Y, Yamamoto M, et al. Epidemiology of invasive fungal infections after liver transplantation and the risk factors of late-onset invasive Aspergillosis. J Infect Chemother 2016; 22(2): 84-9.
[http://dx.doi.org/10.1016/j.jiac.2015.11.005] [PMID: 26683245]
[13]
Nucci M, Marr KA, Vehreschild MJGT, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect 2014; 20(6): 580-5.
[http://dx.doi.org/10.1111/1469-0691.12409] [PMID: 24118322]
[14]
Barchiesi F, Mazzocato S, Mazzanti S, et al. Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. Liver Transpl 2015; 21(2): 204-12.
[http://dx.doi.org/10.1002/lt.24032] [PMID: 25348192]
[15]
Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12(3): 220-9.
[http://dx.doi.org/10.1111/j.1399-3062.2010.00492.x] [PMID: 20113459]
[16]
Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis 2005; 41(1): 52-9.
[http://dx.doi.org/10.1086/430602] [PMID: 15937763]
[17]
Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32(9): 1319-24.
[http://dx.doi.org/10.1086/319985] [PMID: 11303267]
[18]
Silveira FP, Kusne S. Candida infections in solid organ transplantation. Am J Transplant 2013; 13(S4): 220-7.
[http://dx.doi.org/10.1111/ajt.12114] [PMID: 23465015]
[19]
Saliba F, Delvart V, Ichaï P, et al. Fungal infections after liver transplantation: Outcomes and risk factors revisited in the MELD era. Clin Transplant 2013; 27(4): E454-61.
[http://dx.doi.org/10.1111/ctr.12129] [PMID: 23656358]
[20]
Fortún J, Martín-Dávila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8(11): 1065-70.
[http://dx.doi.org/10.1053/jlts.2002.36239] [PMID: 12424722]
[21]
Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18(1): 44-69.
[http://dx.doi.org/10.1128/CMR.18.1.44-69.2005] [PMID: 15653818]
[22]
Osawa M, Ito Y, Hirai T, et al. Risk factors for invasive Aspergillosis in living donor liver transplant recipients. Liver Transpl 2007; 13(4): 566-70.
[http://dx.doi.org/10.1002/lt.21099] [PMID: 17394155]
[23]
Diba K, Afshar A, Rashidi T. Dermatomycosis in renal allograft recipients. Wiley Online Library 2002; 45(52): 12-6.
[24]
Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive Aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006; 42(10): 1417-727.
[http://dx.doi.org/10.1086/503427] [PMID: 16619154]
[25]
Aguilar CA, Hamandi B, Fegbeutel C, et al. Clinical risk factors for invasive aspergillosis in lung transplant recipients: Results of an international cohort study. J Heart Lung Transplant 2018; 37(10): 1226-34.
[http://dx.doi.org/10.1016/j.healun.2018.06.008] [PMID: 30139546]
[26]
Garcia-Vidal C, Barba P, Arnan M, et al. Invasive Aspergillosis complicating pandemic influenza A (H1N1) infection in severely immunocompromised patients. Clin Infect Dis 2011; 53(6): e16-9.
[http://dx.doi.org/10.1093/cid/cir485] [PMID: 21865184]
[27]
Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: Review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37(S3): S188-224.
[http://dx.doi.org/10.1086/376524] [PMID: 12975752]
[28]
Durand ML, Kim IK, D’Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005; 140(3): 552-4.
[http://dx.doi.org/10.1016/j.ajo.2005.03.030] [PMID: 16139017]
[29]
Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system Aspergillosis. Antimicrob Agents Chemother 2005; 49(12): 4867-75.
[http://dx.doi.org/10.1128/AAC.49.12.4867-4875.2005] [PMID: 16304147]
[30]
Ruhnke M, Kofla G, Otto K, Schwartz S. CNS Aspergillosis. CNS Drugs 2007; 21(8): 659-76.
[http://dx.doi.org/10.2165/00023210-200721080-00004] [PMID: 17630818]
[31]
Wasko JA, Westholder JS, Jacobson PA. Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient. J Oncol Pharm Pract 2017; 23(1): 75-9.
[http://dx.doi.org/10.1177/1078155215624263] [PMID: 26763003]
[32]
Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26(12): 1730-44.
[http://dx.doi.org/10.1592/phco.26.12.1730] [PMID: 17125435]
[33]
Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis. Blood 2007; 110(2): 490-500.
[http://dx.doi.org/10.1182/blood-2007-01-069294] [PMID: 17392502]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy